VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests

VolitionRx Ltd. is preparing a reimbursement submission for its Nu.Q Cancer assays to government agencies in France, a move that could establish the blood tests in routine clinical practice for lung cancer management. The submission will be actively supported by Hospices Civils de Lyon, France’s second-largest university hospital system, and will run parallel to the previously announced clinical certification process at the hospital.

Researchers at Hospices Civils de Lyon stated that the Nu.Q Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of both reimbursement and certification processes. Data generated through collaboration with Volition indicate that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care.

The company said the reimbursement submission is expected to be filed under France’s ‘Innovative Procedures Outside the Nomenclature’ framework, which allows early reimbursement support for innovative medical procedures. Volition noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and developing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company’s website at https://www.Volition.com.

The announcement was distributed through BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions. For more information about BioMedWire, visit https://www.BioMedWire.com.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests.

The post VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests appeared first on citybuzz.